196 Effect of the Treatment With Montelukast in Asthmatic Patient

BACKGROUND: Asthma is chronic inflammatory illness of the air roads in which several cells playing an important rol in the development of the bronchial hiperreactivity. The leukotriens are mediators that participate in the inflammatory process being involved in the bronchoconstriction. To evaluate the effectiveness of the Montelukast in patient pediatric and adults with Moderate-Severe Persistent Asthma. METHODS: 201 patients were studied, 101 of 6 to 16 years of age and 100 of 17 or more years old with persistent moderate and severe asthma, without antecedents of illnesses hematológic, hepatic or renal, to those that were administered montelukast in dose from 5 mg of 6 to 14 years and 10 mg to those bigger than this age, once a day during 6 months. A monthly pursuit of its clinical evolution was taken, with control of the renal function and liverwort to the beginning, to the 3 months and when concluding the study; tests of breathing function were also made to the beginning and when finishing the treatment. RESULTS: Neither of the patients worsened, 81% of them passed to stay asymptomatics in this period and 18.9% they happened to fast. In 6 cases it was necessary to move away the treatment for different reasons for causes unaware to the medication. CONCLUSIONS: The effectiveness of this medication was demonstrated and they were not problems of intolerance or important adverse effects.